제 2형 당뇨병 환자에서 Metformin과 병용 시 Dapagliflozin과 Sitagliptin의 효능 비교
Comparisons of Efficacy between Dapagliflozin and Sitagliptin in Combination with Metformin in Type 2 Diabetes Mellitus Patients
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Objectives: This study aimed to compare effects on glycemic control and weight loss between the metformin/dapagliflozincombination and the metformin/sitagliptin combination in type 2 diabetic patients. Methods: This study retrospectively reviewed themedical records, from January 1st 2015 to March 31st 2016, of type 2 diabetic patients who were older than 18 and were prescribedwith dapagliflozin or sitagliptin in combination with metformin. Hemoglobin A1c (HbA1c) levels and weights were measured every 3months. Results: The dapagliflozin group showed a greater decrease in HbA1c levels after 3 months (-0.75% vs. 0.01%, P<0.001), 6months (-0.36% vs. 0.08%, P=0.029), and 9 months (-0.53% vs. 0.08%, P=0.046) compared to the sitagliptin group. Also, thedapagliflozin group showed a greater significant decrease in the rate of change in HbA1c levels after 3 months (-0.09 vs. 0.01,P<0.001), 6 months (-0.04 vs. 0.01, P=0.031), 9 months (-0.07 vs. 0.02, P=0.029), and 12 months (-0.05 vs. 0.05, P=0.047). Furthermore, the dapagliflozin group showed a greater decrease in amount of weight change after 3 months (-2.46 kg vs. 0.37 kg,P<0.001), 6 months (-3.02 kg vs. 0.13 kg, P<0.001), and 9 months (-2.27 kg vs. 0.50 kg, P=0.002). Finally, the dapagliflozin groupshowed a greater decrease in the rate of change in weight after 3 months (-3.10% vs. 0.52%, P<0.001), 6 months (-3.83% vs. 0.21%, P<0.001), 9 months (-2.84% vs. 0.79%, P=0.002), and 12 months (-4.91% vs. 0.44%, P<0.001). Conclusions: It wasconcluded that dapagliflozin is more effective than sitagliptin for type 2 diabetic patients.
Abstract
Objectives: This study aimed to compare effects on glycemic control and weight loss between the metformin/dapagliflozincombination and the metformin/sitagliptin combination in type 2 diabetic patients. Methods: This study retrospectively reviewed themedical records, from January 1st 2015 to March 31st 2016, of type 2 diabetic patients who were older than 18 and were prescribedwith dapagliflozin or sitagliptin in combination with metformin. Hemoglobin A1c (HbA1c) levels and weights were measured every 3months. Results: The dapagliflozin group showed a greater decrease in HbA1c levels after 3 months (-0.75% vs. 0.01%, P<0.001), 6months (-0.36% vs. 0.08%, P=0.029), and 9 months (-0.53% vs. 0.08%, P=0.046) compared to the sitagliptin group. Also, thedapagliflozin group showed a greater significant decrease in the rate of change in HbA1c levels after 3 months (-0.09 vs. 0.01,P<0.001), 6 months (-0.04 vs. 0.01, P=0.031), 9 months (-0.07 vs. 0.02, P=0.029), and 12 months (-0.05 vs. 0.05, P=0.047). Furthermore, the dapagliflozin group showed a greater decrease in amount of weight change after 3 months (-2.46 kg vs. 0.37 kg,P<0.001), 6 months (-3.02 kg vs. 0.13 kg, P<0.001), and 9 months (-2.27 kg vs. 0.50 kg, P=0.002). Finally, the dapagliflozin groupshowed a greater decrease in the rate of change in weight after 3 months (-3.10% vs. 0.52%, P<0.001), 6 months (-3.83% vs. 0.21%, P<0.001), 9 months (-2.84% vs. 0.79%, P=0.002), and 12 months (-4.91% vs. 0.44%, P<0.001). Conclusions: It wasconcluded that dapagliflozin is more effective than sitagliptin for type 2 diabetic patients.
참고문헌 (21)
- Schellenberg ES, "Lifestyle Interventions for Patients With and at Risk for Type 2 DiabetesA Systematic Review and Meta-analysis", Ann Intern Med, 159(8), pp.543~551 (2013)
- Tuomilehto J, "Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance", N Engl J Med, 344(18), pp.1343~1350 (2001)
- Holman RR, "10-year follow-up of intensive glucose control in type 2 diabetes", N Engl J Med, 359(15), pp.1577~1589 (2008)
- 오지영, "당뇨병 진료지침 -대한당뇨병학회, 미국당뇨병학회, 유럽당뇨병학회, 일본당뇨병학회 권고안-", 대한내과학회지, 75(3), pp.249~256 (2008), 대한내과학회
- "FDA®"[URL]
- "Kimsonline®"[URL]
- "Uptodate®"[URL]
- Bailey CJ, "Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomized, double-blind, placebo-controlled trial", Lancet, 375(9733), pp.2223~2233 (2010)
- Bailey CJ, "Dapagliflozin addon to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial", BMC Med, 11, pp.193~ (2013)
- Bolinder J, "Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin", J Clin Endocrinol Metab, 97(3), pp.1020~1031 (2012)
- Strojek K, "Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial", Diabetes Obes Metab, 13(10), pp.928~938 (2011)
- Rosenstock J, "Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy", Diabetes Care, 35(7), pp.1473~1478 (2012)
- Jabbour SA, "Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24 week, multicenter, randomized, double-blind, placebo-controlled study", Diabetes Care, 37(3), pp.740~750 (2014)
- Ferrannini E, "Dapagliflozin in monotherapy in type 2 diabetes patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebocontrolled, phase 3 trial", Diabetes Care, 33(10), pp.2217~2224 (2010)
- Zhang Y, "Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas-a meta-analysis from randomized clinical trials", Diabetes Metab Res Rev, 30(3), pp.241~256 (2014)
- Karagiannis T, "Dipeptidyl peptidase-4inhibitors for treatment of type 2 diabetes mellitus in the clinical setting:systematic review and meta-analysis", BMJ, 344, pp.e1369~e1383 (2012)
- DeFronzo RA, "Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies : a metaanalysis of randomized clinical trials", Diabet Med, 27(3), pp.309~317 (2010)
- Bloomgarden ZT, "Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy", Diabetes Care, 29(9), pp.2137~2139 (2006)
- Skolnik N, "Dapagliflozin in the treatment of patients with type 2 diabetes presenting with high baseline A1C", Postgrad Med, 128(4), pp.356~363 (2016)
- Grandy S, "Changes in weight loss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin", Diabetes Obes Metab, 16(7), pp.645~650 (2014)